# Briumvi (ublituximab-xiiy) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ublituximab-xiiy

> The FDA approved Briumvi (ublituximab-xiiy), sponsored by TG THERAPEUTICS, INC. (TGTX), on December 28, 2022 for to treat relapsing forms of multiple sclerosis.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Briumvi (ublituximab-xiiy) FDA approved?

Yes. The FDA approved Briumvi (ublituximab-xiiy), sponsored by TG THERAPEUTICS, INC. (TGTX), on December 28, 2022 for to treat relapsing forms of multiple sclerosis. FDA novel drug approvals: "Briumvi | ublituximab-xiiy | 12/28/2022 | To treat relapsing forms of multiple sclerosisDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/ublituximab-xiiy)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/ublituximab-xiiy#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Briumvi (ublituximab-xiiy) |
| Codes |  |
| Sponsor | TG THERAPEUTICS, INC. (TGTX) https://sec-api.dev/companies/tgtx/catalysts |
| Indications | To treat relapsing forms of multiple sclerosis |
| Modality | biologic |
| FDA designations | none disclosed |

## Timeline

### December 28, 2022: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat relapsing forms of multiple sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Briumvi | ublituximab-xiiy | 12/28/2022 | To treat relapsing forms of multiple sclerosisDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022
- openFDA Drugs@FDA: "BLA761238 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20221228, review_priority STANDARD; sponsor_name TG THERAPEUTICS, INC; product BRIUMVI (UBLITUXIMAB-XIIY)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761238%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ublituximab-xiiy.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Briumvi (ublituximab-xiiy) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ublituximab-xiiy

```bibtex
@misc{secapidev_pdufa_ublituximab_xiiy_20261116,
  title        = {Briumvi (ublituximab-xiiy) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ublituximab-xiiy}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ublituximab_xiiy_20261116","title":"Briumvi (ublituximab-xiiy) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ublituximab-xiiy","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
